Shalwitz, Robert,Hartman, Charlotte,Buch, Akshay,Shalwitz, Isaiah,Janusz, John,Gardner, Joseph
申请号：
NZ75390414
公开号：
NZ753904A
申请日:
2014.06.04
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Provided herein is a tablet formulation comprising an intra-granular component and an extra-granular component, wherein the intra-granular component comprises { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, and sodium starch glycolate； and wherein the extra-granular component comprises sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. Also provided is the use of the tablet formulation in the preparation of a medicament for treating anemia secondary to non-dialysis dependent chronic kidney disease, wherein the medicament is prepared to be administered to a patient having anemia secondary to non-dialysis dependent chronic kidney disease in a dosage regimen comprising a daily dose of a compound which is { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, or a pharmaceutically acceptable salt thereof, wherein the daily dose comprises 150 mg, 300 mg, 450 mg, 600 mg, or 750 mg of the compound.
